Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine

Journal of Clinical Psychopharmacology

Volumn 24, Issue 4, 2004, Pages 389-399

  Goldstein, David J ^a,b   Lu, Yili ^c   Detke, Michael J ^b,c,d,e   Wiltse, Curtis ^c   Mallinckrodt, Craig ^c   Demitrack, Mark A ^f  

^a PRN Consulting   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d MCLEAN HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Neuronetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANOREXIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OUTCOMES RESEARCH; PAIN; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINITIS; SIDE EFFECT; SOMNOLENCE; SWEATING; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAROXETINE; SLEEP INITIATION AND MAINTENANCE DISORDERS; THIOPHENES;

EID: 3242707697     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000132448.65972.d9     Document Type: Article

References (40)

1. Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry. 1999;60:4-9.
2. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128-1132.
3. Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother. 2000;1:917-933.
4. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
5. Tran PV, Bymaster FP, McNamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol. 2003;23:78-86.
6. Fishbain DA, Cutler R, Rosomoff HL, et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain. 1997;13:116-137.
7. Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry. 1993;150:734-741.
8. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med. November 8, 1993;153:2474-2480.
9. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med. October 28, 1999;341:1329-1335.
10. Kellner R, Sheffield BF. The one-week prevalence of symptoms in neurotic patients and normals. Am J Psychiatry. 1973;130:102-105.
11. Zung WW, King RE. Identification and treatment of masked depression in a general medical practice. J Clin Psychiatry. 1983;44:365-368.
12. Abbott FV, Franklin KB, Westbrook RF. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain. 1995;60:91-102.
13. Jones SL. Descending noradrenergic influences on pain. Prog Brain Res. 1991;88:381-394.
14. Richardson BP. Serotonin and nociception. Ann NY Acad Sci. 1990;600:511-519.
15. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
16. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res. 2002;58:169-222.
17. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-315.
18. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36(6):383-390.
19. Goldstein DJ, Mallinckrodt CH, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
20. Faries DE, Heiligenstein JH, Tollefson GD, et al. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol. 2001;21(6):561-568.
21. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-23.
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
24. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
25. DeLoach LJ, Higgins MS, Caplan AB, et al. The Visual Analog Scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998;86:102-106.
26. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health; 1976:76-338.
27. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy. 1992;22:307-319.
28. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25-40.
29. Mallinckrodt CH, Clark WS, David SR. Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCF. Drug Inf J. 2001;35:1215-1225.
30. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11:9-21.
31. Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry. 2001;62:12-16.
32. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry. 1992;53:21-26.
33. Khan A, Detke MJ, Khan SRF, et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;19:211-218.
34. Thase ME, Y Lu, MJ Joliat, et al. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Presented at: 156th American Psychiatric Association Meeting; May 17, 2003; San Francisco, CA.
35. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry. 1999;60:7-11.
36. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry. 2000;7:257-277.
37. Lautenbacher S, Krieg JC. Pain perception in psychiatric disorders: a review of the literature. J Psychiatr Res. 1994;28:109-122.
38. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry. 1997;154:1757-1759.
39. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry. 1993;150(suppl 4):1-26.
40. WHO Mental Health Collaborating Centres, Pharmacotherapy of depressive disorders. A consensus statement. J Affect Disord. 1989;17:197-198.